drugset / Trial / NCT04228263

Hydroxychloroquine and Unexplained Recurrent Miscarriage

NCT04228263

Completed 156 enrolled Assiut University
RandomizedParallel-groupOpen-labelPrevention

Summary

Recurrent miscarriage affects women of childbearing age worldwide. Vascular endothelial dysfunction and immunological impairment are associated with recurrent miscarriage To date, there is no effective or optimal therapeutic approach for these condition. Hydroxychloroquine has endothelial protective action via ant diabetic, lipid lowering, antioxidant effects or direct endothelial protection. Hydroxychloroquine is an antimalarial and immunomodulatory agent. In pregnancy, hydroxychloroquine is prescribed for inflammatory conditions associated with adverse perinatal outcomes such as systemic lupus erythematosus, antiphospholipid syndrome and placental inflammatory lesions such as chronic histiocytic intervillositis, hydroxychloroquine has therapeutic potential to improve placental function in pregnancies associated with heightened inflammation.

Timeline

Start
2020-01-01
Primary completion
2023-03-10
Completion
2023-07-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Hydroxychloroquine Small molecule 400 mg
Background Aspirin Small molecule 75 mg
Background folic acid Other / unclassified 5 mg